PJP is trading at $135.14 (+4.86%), supported by a pharmaceutical-sector rally after strong results and raised guidance.

  • Eli Lilly, Merck and Bristol Myers Squibb reported strong results and raised guidance; Gilead beat expectations and lifted its outlook.
  • Pharmaceutical stocks advanced even as technology shares weighed on the broader market, supporting a sector-rotation explanation for PJP’s rise.
  • PJP is a diversified pharmaceutical ETF; no direct PJP-specific announcement was identified.